Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus SEGLUROMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus SEGLUROMET.
ACTOPLUS MET XR vs SEGLUROMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
SEGLUROMET is a fixed-dose combination of ertugliflozin and metformin. Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
Initial: 2.5 mg ertugliflozin/1000 mg metformin twice daily. Titrate based on efficacy and tolerability. Maximum: 5 mg ertugliflozin/2000 mg metformin twice daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Ertugliflozin: terminal half-life ~16.6 hours (range 10-20 h), supporting once daily dosing. Metformin: terminal half-life ~6.2 hours (range 4-8.7 h) in patients with normal renal function; prolonged in renal impairment.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Segluromet (ertugliflozin and metformin) is primarily excreted via renal (ertugliflozin: ~40.9% unchanged in urine; metformin: ~90% unchanged in urine) and fecal/biliary routes (ertugliflozin: ~50.2% in feces as parent and metabolites; metformin: <1% in bile).
Category C
Category C
Thiazolidinedione/Biguanide Combination
SGLT2 Inhibitor/Biguanide Combination